Back HCV Treatment

HCV Treatment

July 28 Is World Hepatitis Day [VIDEO]

July 28 is World Hepatitis Day, an opportunity to raise awareness about viral hepatitis and its consequences. This year's theme -- "Think Again" -- emphasizes that while hepatitis B and C are major causes of death worldwide, viral hepatitis remains remarkably neglected. The World Health Organization (WHO) and others held a press briefing at the 20th International AIDS Conference last week in Melbourne to raise awareness.

alt

Read more:

AIDS 2014: AbbVie Hepatitis C Treatment Works Well for People on Methadone or Buprenorphine

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.

alt

Read more:

Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C

Bristol-Myers Squibb's all-oral dual regimen of daclatasvir (Daklinza) plus asunaprevir (Sunvepra) has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

AIDS 2014 website

7/25/14

alt

Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs

Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.

alt

Read more: